首页> 外文会议>Conference on Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases >Evaluating the potential for resistance development to antimicrobial blue light (at 405 nm) against Gram-negative bacteria: in vitro and in vivo studies
【24h】

Evaluating the potential for resistance development to antimicrobial blue light (at 405 nm) against Gram-negative bacteria: in vitro and in vivo studies

机译:评估抗性发育的潜力,对革兰阴性细菌(405nm)对革兰氏阴性细菌的潜力:体外和体内研究

获取原文

摘要

With the increasing number of pathogenic microbes that are becoming resistant to routinely used antimicrobials, it isimportant to look to non-traditional approaches for the treatment of infections. Antimicrobial blue light (aBL;405 nm)is a novel strategy for the treatment of infections. Here we report an investigation into the potential for resistancedevelopment to aBL in three clinically important Gram-negative bacteria, through sequential exposure in vitro and invivo. We found that 20 cycles of aBL exposure, in vitro, did not incur resistance development, in any of the speciestested (Acinetobacter baumanii, Pseudomonas aeruginosa or Escherichia coli). In addition, sub-curative sequentialaBL treatment of a wound infected with a bioluminescent variant of the P. aeruginosa PAO1 strain, did not influencesensitivity to aBL. In conclusion, it is unlikely that sequential treatment of aBL will result in resistance generation,suggesting that multiple treatments of aBL may be administered without resistance development becoming a concern.
机译:随着越来越多的致病微生物,其变得抵抗常规使用的抗微生物剂,它是对于治疗感染的非传统方法来说很重要。抗微生物蓝光(ABL; 405 nm)是一种治疗感染的新策略。在这里,我们向抵抗潜力报告调查在三个临床上重要的革兰氏阴性细菌中的开发,通过在体外顺序暴露体内。我们发现,在任何物种中,在体外,体外没有产生抗性发育的20个循环经过测试(肺杆菌,铜绿假单胞菌或大肠杆菌)。此外,子治疗顺序Abl治疗伤口感染的铜绿假单胞菌菌株的生物发光变体,没有影响对ABL的敏感性。总之,Abl的顺序治疗不太可能会导致耐药性,建议可以在没有抵抗的情况下给予多重治疗ABL成为一个问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号